

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 8. (Cancelled)

9. (Currently Amended) A method of inhibiting tumor cell growth in a mammal, comprising administering to said mammal a composition comprising a thrombospondin polypeptide and an inhibitor of DNA topoisomerase I enzyme activity, wherein said tumor cell is a colon tumor cell, wherein said thrombospondin polypeptide is thrombospondin-1 (TSP-1) or thrombospondin-2 (TSP-2) and said inhibitor of DNA topoisomerase I enzyme activity is a water soluble camptothecin compound, and wherein administering the composition produces a synergistic antineoplastic effect in said mammal such that tumor growth is inhibited in the presence of said thrombospondin polypeptide and said water soluble camptothecin compound compared to in the absence of said thrombospondin polypeptide and said water soluble camptothecin compound.

10. – 11. (Cancelled)

12. (Previously Presented) The method of claim 9, wherein said thrombospondin polypeptide is thrombospondin-1.

13. (Previously Presented) The method of claim 9, wherein said thrombospondin polypeptide is thrombospondin-2.

14. (Previously Presented) The method of claim 11, wherein said water-soluble camptothecin compound is irinotecan (CPT-11).

15. (Previously Presented) The method of claim 11, wherein said water-soluble camptothecin compound is topotecan.

16. (Cancelled).

- ⁴
~~17~~. (Original) The method of claim ~~9~~, wherein said mammal is a human.
- ⁵
~~18~~. (Previously Presented) The method of claim ~~9~~, wherein said thrombospondin polypeptide is administered prior to said inhibitor of DNA topoisomerase I enzyme activity.
- ⁶
~~19~~. (Previously Presented) The method of claim ~~9~~, wherein said inhibitor of DNA topoisomerase I enzyme activity is administered prior to said thrombospondin polypeptide.
- ⁷
~~20~~. (Previously Presented) The method of claim ~~9~~, wherein said thrombospondin polypeptide and said inhibitor of DNA topoisomerase I enzyme activity are administered simultaneously.